Clinical Trials Browser

Phase 1/2 × Fallopian Tube Neoplasms × tremelimumab × Clear all

NCT02571725 2025-05-23

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Phase 1/2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms